PYC reports Phase II success in treating degenerative blindness condition
PYC Therapeutics (ASX:PYC) has reported its investigational drug candidate, VP-001, has shown success in patients with Retinitis Pigmentosa type 11 (RP11) in Phase 1/2 clinical trials where improvements were reported by patients for up to 18 months after treatment. Listen to the HotCopper podcast...
Market Cap $291.3M
!
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| LF1 | Ann: Equal Access Buy Back Booklet (December 2025) | 13/11/25 | 0 | 70 | |||
|
|||||||
| LF1 | Ann: Notification of buy-back - LF1 | 13/11/25 | 0 | 59 | |||
|
|||||||
| LF1 | Ann: Application for quotation of securities - LF1 | 12/11/25 | 0 | 73 | |||
|
|||||||
| LF1 | Ann: LF1 Monthly Investor Report - October 2025 | 12/11/25 | 0 | 114 | |||
|
|||||||
| LF1 | Ann: Update - Dividend/Distribution - LF1 | 07/11/25 | 0 | 85 | |||
|
|||||||
| LF1 | Ann: Net Tangible Asset Backing | 07/11/25 | 0 | 96 | |||
|
|||||||
| LF1 | Ann: Notification of buy-back - LF1 | 29/10/25 | 0 | 82 | |||
|
|||||||
| LF1 | Ann: Dividend/Distribution - LF1 | 27/10/25 | 0 | 91 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
|
|
||||
| View More | |||||
ASX News